Victory Capital Management Inc. boosted its stake in shares of West Pharmaceutical Services Inc. (NYSE:WST) by 6.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 402,990 shares of the medical instruments supplier’s stock after acquiring an additional 25,298 shares during the quarter. Victory Capital Management Inc.’s holdings in West Pharmaceutical Services were worth $39,763,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the business. Ameritas Investment Partners Inc. lifted its position in West Pharmaceutical Services by 1.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 22,011 shares of the medical instruments supplier’s stock worth $2,080,000 after acquiring an additional 415 shares during the period. Cambridge Investment Research Advisors Inc. lifted its position in West Pharmaceutical Services by 15.1% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 3,883 shares of the medical instruments supplier’s stock worth $374,000 after acquiring an additional 510 shares during the period. Bessemer Group Inc. lifted its position in West Pharmaceutical Services by 4.8% during the 3rd quarter. Bessemer Group Inc. now owns 12,510 shares of the medical instruments supplier’s stock worth $1,204,000 after acquiring an additional 578 shares during the period. Retirement Systems of Alabama lifted its position in West Pharmaceutical Services by 0.5% during the 3rd quarter. Retirement Systems of Alabama now owns 138,483 shares of the medical instruments supplier’s stock worth $13,330,000 after acquiring an additional 660 shares during the period. Finally, Eqis Capital Management Inc. lifted its position in West Pharmaceutical Services by 20.1% during the 3rd quarter. Eqis Capital Management Inc. now owns 3,987 shares of the medical instruments supplier’s stock worth $384,000 after acquiring an additional 667 shares during the period. 92.69% of the stock is owned by institutional investors.

A number of analysts have weighed in on the company. Goldman Sachs Group assumed coverage on West Pharmaceutical Services in a research report on Wednesday, January 24th. They set a “neutral” rating and a $110.00 price objective for the company. Zacks Investment Research cut West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th. Wells Fargo & Co increased their price objective on West Pharmaceutical Services from $105.00 to $112.00 and gave the stock an “outperform” rating in a research report on Friday, October 27th. Finally, Bank of America cut West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 price objective for the company. in a research report on Tuesday, October 17th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. West Pharmaceutical Services has a consensus rating of “Hold” and a consensus target price of $108.17.

In other news, CFO William J. Federici sold 21,000 shares of the stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $99.01, for a total transaction of $2,079,210.00. Following the completion of the transaction, the chief financial officer now directly owns 190,493 shares of the company’s stock, valued at approximately $18,860,711.93. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 1.90% of the company’s stock.

West Pharmaceutical Services Inc. (NYSE:WST) opened at $90.42 on Friday. The stock has a market capitalization of $6,995.37, a P/E ratio of 40.61, a PEG ratio of 2.00 and a beta of 1.04. West Pharmaceutical Services Inc. has a one year low of $77.97 and a one year high of $103.36. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.87 and a current ratio of 2.59.

The firm also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Thursday, January 18th were paid a dividend of $0.14 per share. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.62%. The ex-dividend date was Wednesday, January 17th. West Pharmaceutical Services’s dividend payout ratio (DPR) is 22.31%.

ILLEGAL ACTIVITY NOTICE: “Victory Capital Management Inc. Buys 25,298 Shares of West Pharmaceutical Services Inc. (WST)” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2018/02/09/victory-capital-management-inc-buys-25298-shares-of-west-pharmaceutical-services-inc-wst.html.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.